Sosei Heptares Starts New Clinical Development Program
TOKYO and LONDON, Feb. 20, 2019 /PRNewswire/ — Sosei Group Corporation (‘the Company’; TSE: 4565), announces that the first healthy subject has been dosed with a novel small molecule HTL0030310 in a Phase I clinical study, marking the start of a new in-house clinical program… Read More